30 closest matches · ranked by relevance
Choriocarcinoma · FIGO Stage I Gestational Trophoblastic Tumor · FIGO Stage II Gestational Trophoblastic Tumor
Primary: Percentage of Participants With Complete Response — 78.6; 88.5 percentage of participants
Good Prognosis Metastatic Gestational Trophoblastic Tumor · Hydatidiform Mole · Non-Metastatic Gestational Trophoblastic Tumor
Primary: Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay — 57; 76; 48; 29 Participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Choriocarcinoma
Primary: Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma — 18 Months
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Persistent Pregnancy of Unknown Location · Ectopic Pregnancy
Primary: Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy — 31; 42; 45 Participants
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Breast Cancer
Primary: Overall Response Rate (ORR) — 30 percentage of participants
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Gynecologic Tumors
Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Breast Cancer
Primary: Disease Progression — 1; 0 Participants
Neuroendocrine Tumors · Hepatic Metastases · Metastases
Primary: Rate of Hepatic Progression Free Survival at 24 Months — 47; 20 Participants
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Ovarian Cancer
Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001